
Methods: This was a cross-sectional study using nationally representative data from the Medical Expenditure Panel Survey (MEPS) from 2000 to 2010. Eligible cases were limited to women > 18 years of age, who had an ICD-9 CM diagnosis code for either acute cystitis (595) or UTI site unspecified (599). The proportion of visits at which physicians prescribed β-lactams, trimethoprim-sulfamethoxazole, quinolones, or nitrofurantoin were evaluated. Annual prescription rates were reported per 1,000 persons and population estimates were obtained from the U.S. Census Bureau. Data weights were used to derive national estimates.
Results: This cohort represents over 75 million ambulatory care visits for UTIs from 2000 to 2010. The yearly rate of outpatient antibiotic prescriptions for UTIs increased from 40 per 1,000 women in 2000 to 54 per 1,000 women in 2010. The proportion of UTI visits where an antibiotic was prescribed increased from 58% in 2000 to 89% in 2010. The most frequently prescribed antibiotics were quinolones (28%), nitrofurantoin (24%), and trimethoprim-sulfamethoxazole (18%). Nitrofurantoin use increased from 2000 to 2010 (21% v 26%; RR 1.23, 95%CI 1.23-1.25); whereas, β-lactam use (18% v 11%; 0.61, 0.60-0.62) and trimethoprim-sulfamethoxazole use (19% v 15%; 0.78, 0.77-0.79) decreased. Quinolone use remained stable (28% v 28%; 0.99, 0.99-1.00).
Conclusion: Outpatient antibiotic prescribing for UTIs among U.S. women has increased over the last decade. Nitrofurantoin prescribing has increased, β-lactam and trimethoprim-sulfamethoxazole prescribing have decreased, and quinolone prescribing has remained stable. Quinolones were the most frequently prescribed antibiotics over the entire study period, even though they are not highly recommended as first line therapy. This suggests opportunities exist to improve outpatient antibiotic prescribing for UTIs.

G. C. Lee,
None
B. F. Teshome, None
K. Lawson, None
J. S. Lewis II, None
R. T. Attridge, None
C. R. Frei, AstraZeneca: Grant Investigator, Research grant
Bristol Myers Squibb: Grant Investigator, Research grant
Elan: Grant Investigator, Research grant
Forest: Board Member, Consulting fee
Pfizer: Grant Investigator, Research grant
Ortho-McNeil Janssen: Board Member, Consultant and Grant Investigator, Consulting fee and Research grant